Ocugen (NASDAQ:OCGN) Earns Outperform Rating from Analysts at Oppenheimer

Equities researchers at Oppenheimer started coverage on shares of Ocugen (NASDAQ:OCGN) in a research report issued on Wednesday,Benzinga reports. The firm set an “outperform” rating and a $10.00 price target on the stock. Oppenheimer’s target price would suggest a potential upside of 464.97% from the stock’s current price.

Several other brokerages have also recently commented on OCGN. Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Wall Street Zen cut Ocugen from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research report on Thursday, March 5th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Ocugen currently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Ocugen Price Performance

NASDAQ OCGN opened at $1.77 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 8.04. Ocugen has a 12-month low of $0.52 and a 12-month high of $2.00. The company has a market capitalization of $580.38 million, a PE ratio of -7.70 and a beta of 2.75. The firm’s 50 day moving average is $1.59 and its 200-day moving average is $1.44.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Wednesday, March 4th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The business had revenue of ($0.19) million during the quarter, compared to analysts’ expectations of $0.86 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. Equities research analysts anticipate that Ocugen will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Ocugen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SmartHarvest Portfolios LLC acquired a new position in shares of Ocugen during the 4th quarter worth about $31,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Ocugen in the 4th quarter valued at about $38,000. Verdence Capital Advisors LLC acquired a new stake in Ocugen in the 3rd quarter valued at about $47,000. Cora Capital Advisors LLC lifted its stake in Ocugen by 27.5% in the 4th quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after purchasing an additional 6,500 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Ocugen by 28,222.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock worth $41,000 after purchasing an additional 30,198 shares during the period. 10.27% of the stock is owned by institutional investors.

Ocugen News Summary

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised several 2026 quarterly and FY2026 EPS forecasts (Q1–Q3 moved to ($0.06), Q4 to ($0.07), FY2026 to ($0.24) from ($0.29)), signaling slightly improved near‑term profitability expectations. Read More.
• Positive Sentiment: Ocugen announced completion of enrollment in the Phase 3 trial of OCU400, a key operational milestone that de‑risks timing for pivotal data readouts and potential value inflection. Read More.
• Positive Sentiment: Company-released 2025 results and updates highlighted clinical progress across its gene‑therapy pipeline, supporting development momentum beyond single program headlines. Read More.
• Neutral Sentiment: HC Wainwright published an optimistic long‑term FY2030 EPS projection ($1.04), but this is a high‑uncertainty, model‑driven figure that may have limited near‑term market impact. Read More.
• Negative Sentiment: HC Wainwright trimmed multi‑year forecasts (FY2027, FY2028 and FY2029 estimates were reduced — FY2029 notably cut from $0.84 to $0.26), signaling weaker medium‑to‑longer‑term revenue/profit expectations and increased uncertainty around commercialization/timing. Read More.
• Negative Sentiment: A Seeking Alpha piece recommended downgrading the stock following OCU410 data, which could weigh on sentiment among value and momentum investors focused on near‑term data. Read More.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.